2008
DOI: 10.1310/hpj4306-491
|View full text |Cite
|
Sign up to set email alerts
|

Improving Heparin Safety: A Multidisciplinary Invited Conference

Abstract: Heparin is widely used in a variety of settings for prevention and treatment of thromboembolic events. Data from a number of sources indicate that it is also one of the drugs most frequently associated with adverse events and medication errors, many of which are serious. National media attention has focused on recent events involving heparin and The Joint Commission has included heparin in its 2009 National Patient Safety Goal to reduce patient harm from anticoagulants. Heparin safety is on the national agenda… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2009
2009
2011
2011

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…Despite its ubiquity in clinical settings, bleeding is a common and serious complication of heparin therapy [1,2]. Therapeutic UFH is a naturally occurring glycosaminoglycan that is purified from pig or bovine tissue as a heterogeneous mixture of polysaccharide chains with variable molecular weight (5–30 kDa, average 15 kDa) [3,4].…”
mentioning
confidence: 99%
“…Despite its ubiquity in clinical settings, bleeding is a common and serious complication of heparin therapy [1,2]. Therapeutic UFH is a naturally occurring glycosaminoglycan that is purified from pig or bovine tissue as a heterogeneous mixture of polysaccharide chains with variable molecular weight (5–30 kDa, average 15 kDa) [3,4].…”
mentioning
confidence: 99%
“…In response to recent errors, there have been several conferences convened on medication safety, including a multidisciplinary invited conference on improving heparin safety sponsored by Cardinal Health Center for Safety and Clinical Excellence in March 2008. 5 At this conference, participants from ISMP, USP, the Joint Commission, academic institutions, large health care systems, and small hospitals discussed issues surrounding the safe administration of heparin. Material presented addressed the frequency and distribution of heparin errors; clinical issues with the use of heparin, such as variations in dosing protocols, appropriate timing of tests for monitoring heparin safety, and the sensitivity of reagents used for monitoring of heparin therapy; programming errors with the use of infusion devices for heparin; lack of human-factors considerations involved in process and device use with heparin; and recommendations to improve heparin safety within health care organizations.…”
Section: Concurrent Safety Conferencesmentioning
confidence: 99%